News | January 4, 2021

Passage Bio Receives FDA Clearance of IND Application for Lead Gene Therapy Candidate PBGM01 for Treatment of Infantile GM1 Gangliosidosis FDA clearance marks second regulatory authorization for global Phase 1/2 clinical trial, Imagine-1 study, expected to dose first...

News | December 15, 2020

Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock NEW HAVEN, Conn., Dec. 15, 2020 (GLOBE NEWSWIRE) — Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein...

News | December 14, 2020

Arvinas Releases Interim Clinical Data Further Demonstrating the Powerful Potential of PROTAC® Protein Degraders ARV-471 and ARV-110 – ARV-471 demonstrates evidence of anti-tumor activity, and potential for best-in-class safety, and estrogen receptor (ER) degradation...

News | November 30, 2020

Deciphera Pharmaceuticals Completes Target Enrollment in the INTRIGUE Phase 3 Clinical Study of QINLOCK® (Ripretinib) in Patients with Second-Line Gastrointestinal Stromal Tumor – Top-line Results Expected in Second Half of 2021 –– Study Designed to Evaluate the...

News | December 8, 2020

Kit Check Launches Streamlined Mobile Pharmacy to Boost EfficiencyLucas McCanna December 8, 2020Medication management easily accessible through stocked medication cart WASHINGTON (December 8, 2020) — Kit Check, the leader in automated and intelligent medication...

News | December 17, 2020

Kyruus and HealthSparq Come Together to Transform Care Navigation Through Novel Payer-Provider Collaboration Kyruus Acquisition of HealthSparq from Cambia Health Solutions Provides Unparalleled Digital Access Platform to Connect People to the Right Care for Their...